News | January 07, 2025
Japan Health Authority approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara
The biosimilar Ustekinumab has been developed and manufactured by the company
The biosimilar Ustekinumab has been developed and manufactured by the company
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
We now rank 3rd in pharmaceutical production by volume and 14th by value
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
